[{"data":1,"prerenderedAt":28},["ShallowReactive",2],{"$fsxh23Dd1hoSA1I8g0ivb-iTQib9GoZGqamWwR1BZeaI":3},{"code":4,"show":5,"msg":6,"data":7,"status":27},1,0,"",{"info":8,"next":17,"prev":21,"others":24},{"cate_name":9,"id":10,"cid":11,"title":12,"desc":13,"image":14,"content":15,"is_show":4,"home_recommend":4,"publish_at":16},"好物",4,3,"SciBrunch Therapeutics Completes Over  35 Million Pre-A Round Financing, Totaling 65 Million in Two Recent Rounds","SciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.","https://api-scibrunch.hellokoma.com/uploads/images/20260416/20260416153543a1ff13477.jpg","\u003Cp>\u003Cspan style=\"font-family: Arial;\">SciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">This round was led by H\u003C/span>ighLight Capital\u003Cspan style=\"font-family: Arial;\">, a prominent investor in the biopharmaceutical sector, with participation from InnoPinnacle Fund. Existing shareholders including Han\u003C/span>Kang\u003Cspan style=\"font-family: Arial;\"> Capital, B\u003C/span>ioTrack\u003Cspan style=\"font-family: Arial;\"> Capital, LongRiver Investment\u003C/span>s\u003Cspan style=\"font-family: Arial;\">, and \u003C/span>Elikon Venture\u003Cspan style=\"font-family: Arial;\"> also increased their investment.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">This marks another financing round completed by SciBrunch within one year following its angel round in June 2025, bringing the total capital raised in the two rounds to $65 million.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">The proceeds of this financing round will be mainly used for:\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cul>\u003Cli>\u003Cspan style=\"font-family: Arial;\">Accelerating the clinical development of its core pipeline candidate SPR1020, a next-generation highly selective PARP1 inhibitor with significant brain penetration potential. The first patient was dosed on January 8, 2026.\u003C/span>\u003C/li>\u003C/ul>\u003Cp>\u003Cbr>\u003C/p>\u003Cul>\u003Cli>\u003Cspan style=\"font-family: Arial;\">Advancing IND-enabling studies for a new generation of innovative molecular glue RAS inhibitors, exploring their clinical potential in RAS-mutated refractory tumors including colorectal cancer, pancreatic cancer, and non-small cell lung cancer, with the goal of developing preferred therapies for RAS-driven cancers.\u003C/span>\u003C/li>\u003C/ul>\u003Cp style=\"text-align: left;\">\u003Cbr>\u003C/p>",1776149657,{"publish_time":18,"id":4,"title":19,"publish_at":20},"2026-04-09","SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs",1775712312,{"publish_time":18,"id":11,"title":22,"publish_at":23},"First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020",1775712313,[25,26],{"publish_time":18,"id":11,"title":22,"publish_at":23},{"publish_time":18,"id":4,"title":19,"publish_at":20},200,1776763000811]